J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU)
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial
Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...
The Wall Street Journal on MSN6h
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...
STAT4h
Novo Nordisk is slammed by U.K. trade group for not disclosing payments to health and patient groups
Novo Nordisk was slammed by a U.K. trade group for not disclosing payments to health and patient groups, according to a draft ...
STAT5h
Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
Novo Rises After Experimental Shot Delivers 22% Weight Loss
Novo Nordisk A/S rose the most in a month after an experimental shot delivered as much as 22% weight loss in an early-stage ...
Stocktwits on MSN5h
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...
Novo Nordisk Vaults Above LVMH as Europe's Biggest Company
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again Europe's most-valuable listed company. A pullback in the Danish drug maker's ...